RepliCel Life Sciences Inc.

RP:TSX.V; REPCF:OTCQB

Last:
Change: Change(%):
Volume: Open:
High: Low:
52Wk High: 52Wk Low:

RepliCel Life Sciences Inc. is a regenerative medicine company developing autologous cell therapies that treat functional cellular deficits utilizing cells isolated from a patient's own healthy hair follicles. Phase 2 trials for RCT-A-01, a treatment for chronic Achilles tendinosis, and RCH-01, a treatment for pattern baldness, are planned for 2014. A Phase 1 trial for RCS-01, a treatment for damaged and aging skin, is targeted for 2014. All products utilize the company's proprietary manufacturing and cell expansion platform.